About Ehlers-Danlos Syndrome
Ehlers-Danlos syndrome (EDS) is a heterogeneous group of heritable connective tissue disorders affecting collagen synthesis and function. There are 13 classified subtypes, the most common being hypermobile EDS (hEDS) — the only subtype without a confirmed genetic marker. Vascular EDS (vEDS), caused by COL3A1 mutations, carries the greatest risk of arterial rupture and organ perforation. Clinical trials are active in vEDS, classical EDS, and pain management approaches for hEDS. The EDS community is large, vocal, and actively engaged in research.
Common Clinical Features
Clinical Trial Eligibility Tips
What to know before applying to Ehlers-Danlos Syndrome trials.
EDS subtype determines genetic testing pathways — classical, vascular, kyphoscoliotic, and other subtypes have confirmed genetic markers; hEDS is diagnosed clinically.
Vascular EDS trials require COL3A1 mutation confirmation — get full genetic panel testing from a connective tissue specialist before applying.
The Ehlers-Danlos Society patient registry (HEDGE) connects patients to researchers — registration increases trial notification significantly.
Patient Resources
Find recruiting Ehlers-Danlos Syndrome trials
Search 500,000+ studies from ClinicalTrials.gov, filtered for Ehlers-Danlos Syndrome. Updated daily.